» Articles » PMID: 10495434

Anti-neuroblastoma Antibody ChCE7 Binds to an Isoform of L1-CAM Present in Renal Carcinoma Cells

Overview
Journal Int J Cancer
Specialty Oncology
Date 1999 Sep 25
PMID 10495434
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Immunoprecipitation after cell surface labeling of human neuroblastoma cells showed that the anti-neuroblastoma monoclonal antibody (mAb) chCE7 binds to a 200,000 M(r) cell surface protein. The protein was partially purified by immuno-affinity chromatography from a human renal carcinoma and a human neuroblastoma cell line, which both showed high levels of binding of MAb chCE7. NH(2)-terminal sequences of 18 and 15 amino acid residues were determined. Both sequences isolated from the renal carcinoma and the neuroblastoma cells showed strong homology to human cell adhesion molecule L1 (L1-CAM), and both were characterized by the NH(2)-terminal deletion of 5 amino acids, comprising exon 2 of L1-CAM. Reverse trancription-polymerase chain reaction (RT-PCR) analysis of the regions spanning exon 2 and exon 27 of L1-CAM indicated that in neuroblastoma cells both transcripts for the full-length and exon-deleted forms are present, whereas in the renal carcinoma cell lines only the exon-deleted L1-CAM isoform were detected. Western blot analysis showed that 6 of 7 tested renal carcinoma cell lines and 5 of 15 renal carcinoma tissues expressed L1-CAM. In normal adult kidney tissue, very low levels of protein expression were found. Northern blot analysis confirmed that in renal carcinoma and neuroblastoma cell lines L1-CAM mRNA levels are correlated with protein expression.

Citing Articles

Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.

Timpanaro A, Piccand C, Uldry A, Bode P, Dzhumashev D, Sala R Int J Mol Sci. 2023; 24(3).

PMID: 36768928 PMC: 9917031. DOI: 10.3390/ijms24032601.


The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better.

Mao R, Kong W, He Y Front Immunol. 2022; 13:1032403.

PMID: 36325345 PMC: 9618871. DOI: 10.3389/fimmu.2022.1032403.


Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Li N, Spetz M, Li D, Ho M Pharmacol Ther. 2021; 223:107892.

PMID: 33992682 PMC: 8202769. DOI: 10.1016/j.pharmthera.2021.107892.


L1CAM is involved in lymph node metastasis via ERK1/2 signaling in colorectal cancer.

Fang Q, Zheng X, Zhao H Am J Transl Res. 2020; 12(3):837-846.

PMID: 32269716 PMC: 7137048.


Novel Therapeutic Strategies for Ovarian Cancer Stem Cells.

Terraneo N, Jacob F, Dubrovska A, Grunberg J Front Oncol. 2020; 10:319.

PMID: 32257947 PMC: 7090172. DOI: 10.3389/fonc.2020.00319.